Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2004

View Archived Issues

Prous Science announces publication of a comprehensive review on sleep apnea

Takeda presents metastin derivatives for cancer therapy and other uses

New monoamine reuptake inhibitors developed at NeuroSearch

Novel chemokine CCR3 modulators and their use described by Boehringer Ingelheim

Two series of PTP inhibitors presented by TransTech researchers

Novel ALK4/ALK5 inhibitors discovered at Biogen Idec

New androgen receptor antagonists in early development at Pfizer

New Nurr1 activators with potential utility in PD therapy

New p38 MAP kinase inhibitors and their use claimed by Pfizer

Novo Nordisk updates program progress

Canadian approval for Lipitor to lower risk of heart attack

E.U. regulators to review long-term cardiovascular safety data for COX-2 inhibitors

Clinical investigators meeting endorses phase II ThromboView study

Transition Therapeutics sells Stem Cell Therapeutics to Neurogenesis Biotech

Takeda signs agreement to market Tavocept in U.S. and Canada

European approval sought for Surfaxin

Phase II study set to open this month evaluating Zyflo for acne

Small-molecule GSK-3 inhibitor stimulates bone formation in vitro and in vivo

Synthetic peptide promotes fracture healing in mouse model

Combination therapy overcomes resistance of prostate cancer cells to apoptosis

Epothilone derivative promising in human gliomas and drug-resistant melanomas

PI3K antagonist enhances radiation-induced vascular destruction in tumors

Good safety profile of anidulafungin in patients with invasive candidiasis

Clinical trials confirm the antifungal efficacy and safety of posaconazole

Liposomal-encapsulated paclitaxel well tolerated in prostate cancer patients

Development of mycobacterial cell wall-DNA complex advances

Beta-blocking drugs reduce risk of fractures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...